US 12,187,723 B2
Substituted benzimidazolone compounds
Alaric J. Dyckman, Lawrenceville, NJ (US); Laxman Pasunoori, Warangal (IN); Sreekantha Ratna Kumar, Bangalore (IN); Srinivasan Kunchithapatham Duraisamy, Hosur (IN); Pitani Veera Venkata Srinivas, West Godawri (IN); Vikram Bhogadi, Prakasam (IN); and Subramanya Hegde, Bangalore (IN)
Assigned to Bristol-Myers Squibb Company, Princeton, NJ (US)
Appl. No. 17/609,443
Filed by BRISTOL-MYERS SQUIBB COMPANY, Princeton, NJ (US)
PCT Filed May 7, 2020, PCT No. PCT/US2020/031799
§ 371(c)(1), (2) Date Nov. 8, 2021,
PCT Pub. No. WO2020/227484, PCT Pub. Date Nov. 12, 2020.
Claims priority of provisional application 62/845,339, filed on May 9, 2019.
Prior Publication US 2022/0289739 A1, Sep. 15, 2022
Int. Cl. C07D 471/04 (2006.01); C07D 519/00 (2006.01)
CPC C07D 471/04 (2013.01) [C07D 519/00 (2013.01)] 12 Claims
 
1. A compound of Formula (II)

OG Complex Work Unit Chemistry
or a salt thereof, wherein:
each R1 is independently hydrogen, C1-3 alkyl, or —CF3;
each R2 is independently hydrogen, —CH3, or —OCH3;
A is cyclohexyl or piperidinyl, each substituted with zero to 2 R3a;
each R3a is independently C1-6 alkyl, C1-2 cyanoalkyl, C1-4 fluoroalkyl, C2-4 alkoxyalkyl, (CH2)1-3S(O)2(C1-3 alkyl), —CH2(C3-6 cycloalkyl), —CH2Rw, —CH2C(O)NRxRx, —NRyRy, —NRx(C1-3 fluoroalkyl), —NRx(C2-4 alkoxyalkyl), —NRxRw, —NRxCH2Rw, Rw, oxaazaspiro[3.3]heptanyl, dioxothiaazaspiro[3.3]heptanyl, oxaazabicyclo[3.2.1]octanyl, or oxaazaspiro[3.5]nonanyl;
Rw is C3-6 cycloalkyl, azetidinyl, pyrrolidinyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, piperidinyl, piperazinonyl, oxazepanyl, thiomorpholinyl, pyridinyl, pyrimidinyl, or triazolyl, each substituted with zero to 2 substituents selected from F, —OH, C1-3 alkyl, —CF3, —OCH3, —CH2OCH3, and —S(O)2CH3;
each Rx is independently hydrogen or —CH3;
each Ry is independently hydrogen or C1-6 alkyl;
n is zero, 1, or 2; and
p is zero, 1, or 2.